Last edition
News about "Chronic Lymphocytic Leukemia (CLL)"
CHMP Recommends Lilly's Jaypirca for CLL Treatment in EU
CHMP has recommended Lilly’s Jaypirca (pirtobrutinib) for EU approval in adults with chronic lymphocytic leukemia (CLL), potentially expanding its use across all lines of therapy.
Chronic Lymphocytic Leukemia (CLL) | 29/06/2026 | By News Bureau
Lilly's Jaypirca Cuts Disease Progression Risk by 45 Percent in CLL/SLL
Lilly’s Jaypirca (pirtobrutinib) reduced the risk of disease progression or death by 45 percent when combined with a time-limited venetoclax regimen in previously treated CLL/SLL patients, according to phase 3 BRUIN CLL-322 trial results.
Chronic Lymphocytic Leukemia (CLL) | 15/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy